REGENERON PHARMACEUTICALS, INC. Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness
REGENERON PHARMACEUTICALS, INC. (REGN) reported Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-07.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnInterestRateCashFlowHedgeIneffectiveness · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. gain (loss) on interest rate cash flow hedge ineffectiveness for the quarter ending 2018-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on interest rate cash flow hedge ineffectiveness for the quarter ending 2018-06-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on interest rate cash flow hedge ineffectiveness for the quarter ending 2018-03-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on interest rate cash flow hedge ineffectiveness for the quarter ending 2017-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on interest rate cash flow hedge ineffectiveness for fiscal 2018 was $0.00.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on interest rate cash flow hedge ineffectiveness for fiscal 2017 was $0.00.
| Period end | Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness 3 month | Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness 6 month | Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness 9 month | Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-07 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | ||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-03 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-07 | |||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |